Ascendis Pharma price target raised to $332 from $325 at Stifel

Stifel raised the firm’s price target on Ascendis Pharma (ASND) to $332 from $325 and keeps a Buy rating on the shares following the accelerated approval of Yuviwel. The firm thinks the approval represents “a solid win” for Ascendis as they continue to expand their commercial portfolio. Stifel sees upside to shares if the weekly doing versus daily dosing profile drives disruption and increased uptake within the U.S./global Achondroplasia market, the firm told investors in a research note.